Lightbridge Corporation (NASDAQ:LTBR) shares are trading higher Thursday after the company announced a collaboration agreement with Oklo Inc. (NYSE:OKLO).

What To Know: Lightbridge and Oklo entered into a non-binding Memorandum of Understanding (MOU) on Wednesday to explore joint opportunities in nuclear fuel development, according to a new regulatory filing.

The MOU outlines plans for a feasibility study to evaluate co-locating a Lightbridge commercial-scale fuel fabrication facility at Oklo's proposed commercial fuel fabrication site. The companies will also explore opportunities for collaboration on reprocessing and recycling spent uranium-zirconium fuel.

Lightbridge and Oklo shares have soared in recent months, driven by increased optimism around nuclear. Multiple big tech companies have signed deals with nuclear power startups in an effort to keep up with rising energy demands of AI data centers.

How To Buy LTBR Stock

By now you're likely curious about how to participate in the market for Lightbridge – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share. In the case of Lightbridge, which is trading at $9.9 as of publishing time, $100 would buy you 10.1 shares of stock.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

LTBR Price Action: Lightbridge shares were up 40.4% at $10.14 at the time of publication Thursday, according to Benzinga Pro.

Read Next:

• Johnson & Johnson’s MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst

This illustration was generated using artificial intelligence via Midjourney.